PLA2R and membranous nephropathy: A 3 year prospective Australian study

Hill, Prue A., McRae, Jennifer L. and Dwyer, Karen M. 2016, PLA2R and membranous nephropathy: A 3 year prospective Australian study, Nephrology, vol. 21, no. 5, pp. 397-403, doi: 10.1111/nep.12624.

Attached Files
Name Description MIMEType Size Downloads

Title PLA2R and membranous nephropathy: A 3 year prospective Australian study
Author(s) Hill, Prue A.
McRae, Jennifer L.
Dwyer, Karen M.ORCID iD for Dwyer, Karen M. orcid.org/0000-0002-4376-9720
Journal name Nephrology
Volume number 21
Issue number 5
Start page 397
End page 403
Total pages 7
Publisher Wiley
Place of publication London, Eng.
Publication date 2016-05
ISSN 1440-1797
Keyword(s) membranous nephropathy
nephrotic syndrome
pathology
renal
Autoantibodies
Biomarkers
Biopsy
Enzyme-Linked Immunosorbent Assay
Fluorescent Antibody Technique
Glomerulonephritis, Membranous
Humans
Kidney
Predictive Value of Tests
Prospective Studies
Receptors, Phospholipase A2
Reproducibility of Results
Time Factors
Victoria
Summary AIM: The phospholipase A2 receptor (PLA2R) is the major target antigen in idiopathic membranous nephropathy (iMN). The aim of this prospective study was to determine the prevalence of anti-PLA2R in iMN in an Australian cohort. METHODS: Serum anti-PLA2R was measured using two techniques, an enzyme-linked immunosorbent assay (ELISA) and a cell-based indirect immunofluorescence test. Kidney biopsies were also examined for the presence of PLA2R using a polyclonal antibody. A group of 21 patients with iMN were compared with a group of 19 patients with secondary MN and other glomerular diseases. RESULTS: Seventeen of 21 patients with iMN were positive for anti-PLA2R on both ELISA and indirect immunofluorescence test, and 14 of these patients also had positive staining for PLA2R in the biopsy (tissue was unavailable in two patients). Three patients with iMN had positive staining in the biopsy only, and one patient was negative in both the serum and the biopsy. None of the patients with secondary MN or other glomerular diseases had anti-PLA2R antibodies or PLA2R in the biopsy. There was wide inter-individual variation in titre on ELISA, but serial levels within an individual patient enabled monitoring of disease, and a fall in titre correlated with clinical remission. CONCLUSIONS: This is the first Australian series to examine the incidence of anti-PLA2R in iMN. It is also unique in examining sera by two separate techniques in conjunction with tissue localization of PLA2R. We have shown 100% specificity of both serum anti-PLA2R and glomerular PLA2R in iMN, with a sensitivity of 81.0%. When serum testing is combined with tissue localization of PLA2R, the sensitivity increases to 95.2%.
Language eng
DOI 10.1111/nep.12624
Field of Research 1103 Clinical Sciences
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2015, Asian Pacific Society of Nephrology
Persistent URL http://hdl.handle.net/10536/DRO/DU:30110725

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 10 times in TR Web of Science
Scopus Citation Count Cited 12 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 236 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Tue, 10 Jul 2018, 10:49:49 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.